2-(4-morpholinoanilino)-6-cyclohexylaminopurine has been researched along with mpi-0479605 in 3 studies
| Studies (2-(4-morpholinoanilino)-6-cyclohexylaminopurine) | Trials (2-(4-morpholinoanilino)-6-cyclohexylaminopurine) | Recent Studies (post-2010) (2-(4-morpholinoanilino)-6-cyclohexylaminopurine) | Studies (mpi-0479605) | Trials (mpi-0479605) | Recent Studies (post-2010) (mpi-0479605) |
|---|---|---|---|---|---|
| 85 | 0 | 62 | 11 | 0 | 11 |
| Protein | Taxonomy | 2-(4-morpholinoanilino)-6-cyclohexylaminopurine (IC50) | mpi-0479605 (IC50) |
|---|---|---|---|
| Dual specificity protein kinase TTK | Homo sapiens (human) | 0.0029 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bradford, C; Bursavich, M; Carlson, RO; Chan, A; Cimbora, DM; Gerrish, D; Hoarau, C; McKinnon, R; Papac, DI; Patton, S; Reeves, L; Roth, BL; Saunders, M; Shenderovich, M; Slattum, P; Vijay Kumar, D; Williams, BL; Yager, K | 1 |
| Awrey, DE; Ban, F; Beletskaya, I; Bray, MR; Che, Y; Chirgadze, NY; Edwards, L; Feher, M; Fletcher, GC; Forrest, B; Hodgson, R; Kiarash, R; Lang, Y; Laufer, R; Li, SW; Lin, DC; Liu, Y; Madeira, B; Mak, TW; Mao, G; Mason, JM; Ng, G; Patel, NK; Pauls, HW; Plotnikova, O; Qiu, W; Sampson, PB; Wei, X | 1 |
| Jiang, M; Li, C; Li, J; Liang, D; Liu, J; Sun, W; Wang, S; Yang, X; Zhang, C; Zhang, M; Zhou, X | 1 |
1 review(s) available for 2-(4-morpholinoanilino)-6-cyclohexylaminopurine and mpi-0479605
| Article | Year |
|---|---|
Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective.
Topics: Antineoplastic Agents; Cell Cycle Proteins; Drug Design; Drug Resistance; Humans; M Phase Cell Cycle Checkpoints; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Spindle Apparatus; Structure-Activity Relationship; Triple Negative Breast Neoplasms | 2019 |
2 other study(ies) available for 2-(4-morpholinoanilino)-6-cyclohexylaminopurine and mpi-0479605
| Article | Year |
|---|---|
Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors.
Topics: Adenine; Administration, Oral; Animals; Apoptosis; Binding Sites; Crystallography, X-Ray; G2 Phase Cell Cycle Checkpoints; HCT116 Cells; Humans; M Phase Cell Cycle Checkpoints; Mice; Molecular Conformation; Morpholines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Purines; Structure-Activity Relationship | 2012 |
The Discovery of Orally Bioavailable Tyrosine Threonine Kinase (TTK) Inhibitors: 3-(4-(heterocyclyl)phenyl)-1H-indazole-5-carboxamides as Anticancer Agents.
Topics: Administration, Oral; Animals; Cell Cycle Proteins; Cell Line, Tumor; Colon; Colonic Neoplasms; Crystallography, X-Ray; Female; Humans; Indazoles; Mice, Nude; Models, Molecular; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases | 2015 |